Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/15/2005WO2005084673A1 Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
09/15/2005WO2005084671A2 Combination of voriconazole and an antifungal cyp2c19 inhibitor
09/15/2005WO2005084670A1 Pharmaceutical formulation
09/15/2005WO2005084669A1 Pharmaceutical composition
09/15/2005WO2005084668A1 Medicine for prevention and/or treatment of ischemic circulatory disease
09/15/2005WO2005084667A1 Bicyclic and bridged nitrogen heterocycles
09/15/2005WO2005084666A1 Co-formulations of kits of bioactive agents
09/15/2005WO2005084665A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof
09/15/2005WO2005084664A1 Indole derivatives and uses thereof
09/15/2005WO2005084663A1 Hetero-substituted acetanilide derivates as analgesic agents
09/15/2005WO2005084662A1 The euphorbia lunulate bge extractant and production method and use thereof
09/15/2005WO2005084661A1 Antitumor agent
09/15/2005WO2005084660A1 Prevention and measure for mitochondrial disease
09/15/2005WO2005084659A1 Method for inducing cell death with carbonyl scavengers
09/15/2005WO2005084657A1 Compositions and methods for preventing or treating an inflammatory response
09/15/2005WO2005084656A1 Use of new lipoxygenase inhibitors
09/15/2005WO2005084655A1 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
09/15/2005WO2005084654A2 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
09/15/2005WO2005084652A2 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
09/15/2005WO2005084651A2 Methods for altering insulin secretion
09/15/2005WO2005084649A1 Stable capsule preparation
09/15/2005WO2005084647A1 Pharmaceutical composition comprising pimobendan
09/15/2005WO2005084643A1 Crystalline composition containing escitalopram oxalate
09/15/2005WO2005084641A1 Method and apparatus for producing carrier complexes
09/15/2005WO2005084640A1 Stable pharmaceutical solution formulations for pressurized metered dose inhalers
09/15/2005WO2005084637A2 Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
09/15/2005WO2005084636A2 A process for the preparation of controlled-release pharmaceutical composition of metoprolol
09/15/2005WO2005084634A1 Delivery systems for non-steroidal anti-inflammatory drugs (nsaids)
09/15/2005WO2005084632A1 Method and composition for burned skin
09/15/2005WO2005084627A1 Alcohol-free chlorhexidine compositions
09/15/2005WO2005084625A1 Method and composition for treating oral bacteria and inflammation
09/15/2005WO2005084619A1 Composition comprising sodium silicate for use in the treatment of dry skin conditions
09/15/2005WO2005084613A1 Skin preparation for external use
09/15/2005WO2005084612A1 The new usage of elastase inhibitors
09/15/2005WO2005084610A2 New therapeutic use for a group of sulphated polysaccharides
09/15/2005WO2005084463A1 Aggregates of eyeballs of crustaceans, usage, foods coataining the same, and production processes
09/15/2005WO2005084444A1 Compositions and methods for the treatment and clinical remission of psoriasis
09/15/2005WO2005084440A1 Method for increasing muscle mass and strength through administration of adenosine triphosphate
09/15/2005WO2005084439A1 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
09/15/2005WO2005084392A2 4-methylpyrazole formulations for inhibiting ethanol intolerance
09/15/2005WO2005084365A2 Triptolide lactone ring derivatives as immunomodulators and anticancer agents
09/15/2005WO2005084349A2 Compounds useful for the synthesis of (+)-discodermolide and methods therefor
09/15/2005WO2005084323A2 Compositions of bio-active compounds from fenugreek seed and methods for producing same
09/15/2005WO2005084317A2 Dimeric small molecule potentiators of apoptosis
09/15/2005WO2005084307A2 Use of lipid conjugates in the treatment of disease
09/15/2005WO2005084301A2 Compositions and methods for treating diseases
09/15/2005WO2005084296A2 Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
09/15/2005WO2005084295A2 Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
09/15/2005WO2005084230A2 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
09/15/2005WO2005084222A2 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
09/15/2005WO2005084205A2 Diamino thiazoloindan derivatives and their use
09/15/2005WO2005084157A2 Methods of treating disease through the administration of a manzamine analog or derivative
09/15/2005WO2005084129A2 Structured triglycerides and emulsions comprising same
09/15/2005WO2005077366B1 Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells
09/15/2005WO2005072711A3 Method for producing sorbicillactone a
09/15/2005WO2005070079A3 Methods of using zonisamide as an adjunctive therapy for partial seizures
09/15/2005WO2005070078A3 Methods of using zonisamide as an adjunctive therapy for partial seizures
09/15/2005WO2005069731A3 Method for treating oral aphthous stomatitis and oral mucositis
09/15/2005WO2005067931A3 Dopamine uptake inhibitors for the treatment of neurological disease
09/15/2005WO2005067502A3 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
09/15/2005WO2005065050A3 Bicyclic compound
09/15/2005WO2005063254A3 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
09/15/2005WO2005060693A3 9-desoxoerythromycin compounds as prokinetic agents
09/15/2005WO2005060361A3 Pharmaceutical formulations for itraconazole
09/15/2005WO2005058308A3 Treatment for alzheimer's disease and related conditions
09/15/2005WO2005056812A3 Practical, cost-effective synthesis of ubiquinones
09/15/2005WO2005055940A3 Novel m3 muscarinic acetylcholine receptor antagonists
09/15/2005WO2005055935A3 Cationic substituted benzofurans as antimicrobial agents
09/15/2005WO2005054430A3 Hepatitis c virus inhibitors
09/15/2005WO2005054198A3 Therapeutics use of pyridinium compounds to modulate naadp activity
09/15/2005WO2005053702A3 Anti-inflammatory agents
09/15/2005WO2005051300A3 Bicyclic inhibitors of mek and methods of use thereof
09/15/2005WO2005049589A3 Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
09/15/2005WO2005049084A3 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
09/15/2005WO2005048996A3 Modified release dosage forms of skeletal muscle relaxants
09/15/2005WO2005047898A3 Methods and compositions for identifying therapeutic compounds
09/15/2005WO2005046711A3 Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
09/15/2005WO2005046672A3 Use of glucosidase inhibitors for therapy of mucovisidosis
09/15/2005WO2005046578A3 Isoquinolinone potassium channel inhibitors
09/15/2005WO2005044199A3 Combination of proton pump inhibitor and sleep aid
09/15/2005WO2005044130A9 Pdk-1/akt signaling inhibitors
09/15/2005WO2005041922A3 Composition
09/15/2005WO2005039496A3 Inhibitors of cathepsin s
09/15/2005WO2005039484A3 Indolocarbazole anticancer agents and methods of using same
09/15/2005WO2005039443A3 Gamma-tocopherol therapy for restenosis prevention
09/15/2005WO2005038465A3 Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
09/15/2005WO2005037832B1 Azabicycyclic compounds for relieving pain and treating central nervous system disorders
09/15/2005WO2005037258A3 Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
09/15/2005WO2005037189A3 Cytoplasmic activity of retinoid x receptor and its regulation by ligands and dimerization
09/15/2005WO2005034845A3 Compositions and methods for treatment of cancer
09/15/2005WO2005032521A3 Non-flammable topical anesthetic liquid aerosols
09/15/2005WO2005032479A3 Compositions and methods for selective inhibition of nicotine acetylcholine receptors
09/15/2005WO2005030143A3 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
09/15/2005WO2005026111A3 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase
09/15/2005WO2005025504A3 Modulators of calcitonin and amylin activity
09/15/2005WO2005020900A3 Delivery of a therapeutic agent in a formulation for reduced toxicity
09/15/2005WO2005018547A3 Mitotic kinesin inhibitors
09/15/2005WO2005013951A3 Pharmaceutical compositions for preventing breast and ovarian cancer
09/15/2005WO2005013949A3 Method for treating cachexia with retinoid ligands
09/15/2005WO2005009389A3 Anaplastic lymphoma kinase modulators and methods of use
1 ... 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 ... 7860